UGenome AI Announces Partnership with Linkco Health to Reduce Adverse Drug Reactions for people who take multiple medications

for immediate release

May 12, 2025 05:00 a.m. Pacific Standard Time & 8:00 a.m. Eastern Standard Time

TUCSON, A.Z. – UGenome AI, a pioneer in genomic platforms to fuel personalized medicine, today announced a strategic partnership with LinkCo Health to improve medication management for patients who take multiple medications. This collaboration will empower LinkCo and UGenome to give people, clinicians, and providers a way to save the heartache and trouble of adverse drug reactions (ADRs) and save money and time from extra trips to the pharmacy, doctors’ offices, and ER visits. 

In the U.S. alone, ADRs lead to 106,000 deaths¹, 350,000 Hospitalizations², 1.3 million ER Visits², the 4th leading cause of death³ with 6 billion prescriptions annually⁴ costing the United States $528 billion annually⁵. People over the age of 65 are more likely to suffer from ADRs than their counterparts under 65.⁶ One in ten hospital admissions in those aged 65+ is considered ADR-related, with up to 70% of these admissions potentially avoidable.

“We are very happy to partner with LinkCo Health to push beyond a reactive healthcare approach to a preventative healthcare model, particularly older adults – our parents and grandparents – to help reduce disparities and burden on caregivers and family members,” said Zachary Brooks, PhD, founder and CEO of UGenome AI.

In the Richmond area of Virginia, Linkco Health serves aging adults across the community—many of whom face isolation and lack consistent support from family, friends, or healthcare professionals. With over a decade of experience supporting vulnerable populations, we’re closing gaps in care and advancing equitable, high-impact healthcare spurned by UGenome’s Personalized Medication Service and their commitment to move toward preventative medicine. 

“Through UGenome’s Personalized Medication Service, we empower LinkCo Health’s patients to receive tailored drug regimens based on their unique genetic profiles, optimizing medication outcomes in close collaboration with their healthcare providers,” said Jayden Lee, PharmD, UGenome’s Chief Genomics Officer. 

“The collaboration with UGenome will enhance the efficiency of our efforts to improve health outcomes for participants in our Chronic Care Management program and build on our vision is to build a more inclusive and effective system that benefits patients, clinicians, and providers alike,” said Jaynee Sasso, CEO of LinkCo Health.

About UGenome AI

UGenome AI is a startup biotech company focusing on developing genomics software. UGenome AI is advancing genomics analysis and helping patients receive personalized care, faster. Our products stem from our personalized reference genome and pharmacogenomics tools to help patients receive personalized treatments within weeks, not years. For more information, please visit www.ugenome.io.

About LinkCo Health

LinkCo Health is pioneering a transformative approach to healthcare, focusing on prevention, patient engagement, and addressing social determinants of health. Our vision is to create a more equitable and effective healthcare system that benefits patients, clinicians, and healthcare providers alike. With a decade of experience serving vulnerable populations, particularly aging adults, LinkCo Health bridging healthcare access disparities and delivering high-performance health outcomes.

Contacts.

For UGenome AI Inquiries:
Zachary Brooks
[email protected]

For LinkCo Health Inquiries:
Jaynee Sasso
[email protected]

For Media
Emma Bardin
[email protected]

References

1. Hendrix, L. (2023, March 24). Medication side effects: What to do if you have an adverse drug reaction – Vital Record. Vital Record. https://vitalrecord.tamu.edu/medication-side-effects-what-to-do-if-you-have-an-adverse-drug-reaction/
2. Katella, K. (2020, August 31). Do You Really Need All of Those Medications? Yale Medicine. https://www.yalemedicine.org/news/polypharmacy
3. Research, C. for D. E. and. (2020). Preventable Adverse Drug Reactions: A Focus on Drug Interactions. FDA. https://www.fda.gov/drugs/drug-interactions-labeling/preventable-adverse-drug-reactions-focus-drug-interactions
4. Ho, J. Y. (2023). Life Course Patterns of Prescription Drug Use in the United States. Demography. https://doi.org/10.1215/00703370-10965990
5. Watanabe, J. H., McInnis, T., & Hirsch, J. D. (2018). Cost of Prescription Drug–Related Morbidity and Mortality. Annals of Pharmacotherapy, 52(9), 829–837. https://doi.org/10.1177/1060028018765159
6. Earl, T. R., Katapodis, N. D., & Schneiderman, S. R. (2020). Reducing Adverse Drug Events in Older Adults. In www.ncbi.nlm.nih.gov. Agency for Healthcare Research and Quality (US). https://www.ncbi.nlm.nih.gov/books/NBK555524/
7. Cahir, C., Curran, C., Walsh, C., Hickey, A., Brannigan, R., Kirke, C., Williams, D., & Bennett, K. (2023). Adverse drug reactions in an ageing PopulaTion (ADAPT) study: Prevalence and risk factors associated with adverse drug reaction-related hospital admissions in older patients. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1029067